Holding announcement according to article 135 section 2 BörseG (ESMA 2015/1597)
Marinomed Biotech AG: Release according to article 135 section 2 BörseG
Korneuburg (pta043/01.06.2023/16:00 UTC+2) - Release of Announcement according to article 135 section 2 BörseG
Notification of Major Holdings
1. Issuer
Marinomed Biotech AG, Hovengasse 25, 2100 Korneuburg, Austria
2. Reason for notification
Acquisition / disposal of shares with voting rights
3. Details of person subject to the notification obligation
Name: Mohammed Al Sheikh
4. Names of shareholders, if different from declarants (3)
5. Date on which threshold was crossed or reached
30.05.2023
6. Total positions
| % of voting rights attached to shares (total of 7.a.) | % of voting rights through instruments (total of 7.b.1 + 7.b.2) | total of both in % (7.a. + 7.b.) | total number of voting rights of issuer | |
|---|---|---|---|---|
| Resulting situation on the date on which threshold was crossed / reached | 5,19 | 0 | 5,19 | 1,519,167 |
| Position of previous notification | 13,86 | n/a | 13,86 |
7. Notified details of the resulting situation
7.A: Voting rights attached to shares
| ISIN code | absolute direct (Sec 130 BörseG 2018) | absolute indirect (Sec 133 BörseG 2018) | in % direct (Sec 130 BörseG 2018) | in % indirect (Sec 133 BörseG 2018) |
|---|---|---|---|---|
| ATMARINOMED6 | 78,845 | 0 | 5.19 | 0.00 |
| Total: | 78,845 | 5.19 |
7.B.1: Financial / Other Instruments pursuant to Sec. 131 para. 1 No. 1 BörseG 2018
| type of instrument | Maturity / Expiration | Exercise or conversion period | Voting Rights Absolute | Voting Rights in % |
|---|---|---|---|---|
| Total: | 0 | 0 |
7.B.2: Financial / Other Instruments pursuant to Sec. 131 para. 1 No. 2 BörseG 2018
| type of instrument | Maturity / Expiration | Exercise or conversion period | Cash or physical transaction | Voting Rights Absolute | Voting Rights in % |
|---|---|---|---|---|---|
| Total: | 0 | 0 |
8. Information in relation to the person subject to the notification obligation
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer (1.).
9. In case of proxy voting
Date of general meeting:
Voting rights after general meeting:
10. Other useful information
Die Beteiligungsmeldung erfolgt aufgrund der Schwellenüberschreitung wegen dem Erwerb von 78.845 Aktien.
(end)
| Emitter: |
Marinomed Biotech AG Hovengasse 25 2100 Korneuburg Austria |
|
|---|---|---|
| Contact Person: | Pascal Schmidt, CFO | |
| Phone: | +43 2262 90300 | |
| E-Mail: | pascal.schmidt@marinomed.com | |
| Website: | www.marinomed.com | |
| ISIN(s): | ATMARINOMED6 (Share) | |
| Stock Exchange(s): | Vienna Stock Exchange (Official Trade) |